BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1456 related articles for article (PubMed ID: 29059475)

  • 1. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.
    Shih CJ; Chen HT; Chao PW; Kuo SC; Li SY; Yang CY; Tarng DC; Ou SM; Chen YT
    J Hypertens; 2016 Mar; 34(3):567-74; discussion 575. PubMed ID: 26703918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
    Evans M; Carrero JJ; Szummer K; Åkerblom A; Edfors R; Spaak J; Jacobson SH; Andell P; Lindhagen L; Jernberg T
    J Am Coll Cardiol; 2016 Apr; 67(14):1687-97. PubMed ID: 27056774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients: A Nationwide Population-Based Cohort Study.
    Chien SC; Ou SM; Shih CJ; Chao PW; Li SY; Lee YJ; Kuo SC; Wang SJ; Chen TJ; Tarng DC; Chu H; Chen YT
    Medicine (Baltimore); 2015 Oct; 94(43):e1751. PubMed ID: 26512568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J; Lee S
    Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
    Shih CJ; Chu H; Ou SM; Chen YT
    Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.
    Gilbert CJ; Gomes T; Mamdani MM; Hellings C; Yao Z; Garg AX; Wald R; Harel Z; Juurlink DN
    Can J Cardiol; 2013 May; 29(5):586-91. PubMed ID: 23541666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
    Lim S; Choo EH; Choi IJ; Ihm SH; Kim HY; Ahn Y; Chang K; Jeong MH; Seung KB
    J Korean Med Sci; 2019 Nov; 34(45):e289. PubMed ID: 31760711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in Older Nursing Home Residents After Myocardial Infarction: A Retrospective Cohort Study.
    Zullo AR; Riester MR; Erqou S; Wu WC; Rudolph JL; Steinman MA
    Drugs Aging; 2020 Oct; 37(10):755-766. PubMed ID: 32808250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.
    Song PS; Seol SH; Seo GW; Kim DK; Kim KH; Yang JH; Hahn JY; Gwon HC; Ahn Y; Jeong MH; Song YB; Kim DI;
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):439-49. PubMed ID: 26153396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury.
    Brar S; Ye F; James MT; Hemmelgarn B; Klarenbach S; Pannu N;
    JAMA Intern Med; 2018 Dec; 178(12):1681-1690. PubMed ID: 30422153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
    Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
    J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of renin angiotensin system inhibitor on 3-year clinical outcomes in acute myocardial infarction patients with preserved left ventricular systolic function: a prospective cohort study from Korea Acute Myocardial Infarction Registry (KAMIR).
    Kim KH; Choi BG; Rha SW; Choi CU; Jeong MH;
    BMC Cardiovasc Disord; 2021 May; 21(1):251. PubMed ID: 34020593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction.
    Lee JH; Bae MH; Yang DH; Park HS; Cho Y; Lee WK; Jeong MH; Kim YJ; Cho MC; Kim CJ; Chae SC;
    Korean J Intern Med; 2016 Mar; 31(2):267-76. PubMed ID: 26701233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of and risk factors for severe acute kidney injury in children with heart failure treated with renin-angiotensin system inhibitors.
    Terano C; Ishikura K; Miura M; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Ando T; Honda M
    Eur J Pediatr; 2016 May; 175(5):631-7. PubMed ID: 26687571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.
    Leon SJ; Whitlock R; Rigatto C; Komenda P; Bohm C; Sucha E; Bota SE; Tuna M; Collister D; Sood M; Tangri N
    Am J Kidney Dis; 2022 Aug; 80(2):164-173.e1. PubMed ID: 35085685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy.
    Shih CJ; Chen HT; Kuo SC; Li SY; Lai PH; Chen SC; Ou SM; Chen YT
    CMAJ; 2016 May; 188(8):E148-E157. PubMed ID: 27001739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.